ArticleOncoimmunology2013
A CD38/CD203a/CD73 ectoenzymatic pathway independent of CD39 drives a novel adenosinergic loop in human T lymphocytes.
Article in Oncoimmunology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 189 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
189 citing papers in PubMed, 1 synthesis or guideline pooled it, 266 citations in OpenAlex.
- NADFrontiers in neurology · 2026Pooled it
- Cancer associated fibroblast-T cell crosstalk promotes purinergic synthesis in non-small cell lung cancer (NSCLC).Oncoimmunology · 2026Article
- Review
- Nucleotide Metabolism in Health and Disease.MedComm · 2026Review
- The Great Potential of the Cluster of Differentiation 38 (CD38) Inhibitors in the Treatment of Cancer and Age-Related Metabolic dysfunction.ACS medicinal chemistry letters · 2026Article
- Review
- NADInternational journal of molecular sciences · 2026Article
- CD38 endows local antigen-specific TNature immunology · 2026Article
- CAR-T cells with the CD38Cell reports. Medicine · 2026Article
- Role of immune cells in clear cell ovarian cancer: a two-sample bidirectional Mendelian randomization study.Journal of ovarian research · 2026Article
- Immunoregulatory extracellular vesicles in multiple myeloma patients' peripheral blood.Extracellular vesicles and circulating nucleic acids · 2026Article
- Modulating CD38 enzymatic activity during antibody-based immunotherapy in multiple myeloma: a basic science perspective.Frontiers in immunology · 2026Article
- Multifunctional CD38 in the pathogenesis and treatment of B-cell lymphomas.American journal of blood research · 2026Review
- Dual blockade of adenosine AFrontiers in immunology · 2026Article
- Review
- Assessment of adenosinergic activity of small extracellular vesicles in plasma of cancer patients and healthy donors.Oncoimmunology · 2025Article
- CD39 and CD73: biological functions, diseases and therapy.Molecular biomedicine · 2025Review
- Splicing-aware scRNA-Seq resolution reveals execution-ready programs in effector Tregs.PLoS computational biology · 2025Article
- NMRK2 leads to the depletion of CD8Oncogene · 2025Article
- Purin Metabolism Is Crucial for Regulatory T Cell Stability and Function.European journal of immunology · 2025Review
129 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 6 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The tumor microenvironment is characterized by of high levels of extracellular nucleotides that are metabolized through the dynamic and sequential action of cell surface enzymes (ectoenzymes). These ectoenzymes operate according to their spatial arrangement, as part of (1) continuous (molecules on the same cell) or (2) discontinuous (molecules on different cells) pathways, the latter being facilitated by restricted cellular microenvironment. The outcome of this catabolic activity is an increase in the local concentration of adenosine, a nucleoside involved in the control of inflammation and immune responses. The aim of the work presented here was to demonstrate that a previously unexplored enzymatic pathway may be an alternate route to produce extracellular adenosine. Our data show that this new axis is driven by the nucleotide-metabolizing ectoenzymes CD38 (an NAD
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.